Fractyl shows its intestine-resurfacing device for Type 2 diabetes improves insulin resistance, pancreatic function

Fractyl Health posted new data from its device-based, one-time diabetes treatment, showing its approach not only helped lower average blood sugar but also led to improvements in long-term insulin resistance and pancreatic function.

The company’s Revita DMR outpatient procedure runs a water-filled balloon catheter through the initial region of the small intestine known as the duodenum. By applying heat to the intestinal walls, the endoscopic device strips out and helps reset the organ’s mucosal lining, which can thicken over years from dietary fats, sugars and other foods. Those buildups can throw the body’s metabolic hormone production out of balance, which Fractyl believes contributes to the insulin resistance seen in Type 2 diabetes.

The new data, presented during the annual Digestive Disease Week meeting, were gathered from two clinical studies that previously posted benefits in weight loss and glucose level control and also showed some patients could go without insulin doses for at least six months.

Copyright from 【fiercebiotech】